DR REDDYS LABORATORIES LTD (RDY) Form 6-K — Oct 23, 2026
Dr. Reddy's Laboratories reported Q2 FY26 (quarter ended September 30, 2026) revenue of Rs.86,708 million, down 2% year over year, with net profit attributable to equity holders falling 36% to Rs.9,250 million. The profit decline was driven by North America generics revenue down 23% (down 29% in USD terms) on price and volume erosion, PSAI revenue down 12%, and a Semaglutide batch recall in Canada that generated a Rs.710 million provision for expected product returns. Growth markets partially offset the weakness: India revenue rose 17% and Emerging Markets grew 24%, while gross margin compressed to 52.1% from 54.7% a year earlier.
Key figures
- Eps Beat
- 0
- Revenue
- 86708
- Net Income
- 9250
- Revenue Yoy
- -2%
- Total Assets
- 574481
- Cash Position
- 13294
- Dso days
- 104
- Psai q2 yoy
- -12%
- India q2 yoy
- +17%
- Gross margin q2
- 52.1%
- H1 net profit yoy
- -52%
- Q2 net profit yoy
- -36%
- H1 revenue rsmillion
- 167413
- North america q2 yoy
- -23%
- Paragraph iv filings
- 46
- Gross margin prior q2
- 54.7%
- Pending us fda filings
- 80
- Emerging markets q2 yoy
- +24%
- H1 net profit rsmillion
- 13685
- Working capital rsmillion
- 143084
- Operating cash flow h1 rsmillion
- 4357
- North america q2 revenue rsmillion
- 24890
- Semaglutide recall provision rsmillion
- 710
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.